GEMP - Gemphire Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.57
-0.08 (-4.85%)
At close: 4:00PM EDT

1.60 +0.03 (1.91%)
After hours: 7:30PM EDT

Stock chart is not supported by your current browser
Previous Close1.65
Open1.66
Bid1.43 x 1000
Ask1.67 x 1000
Day's Range1.55 - 1.70
52 Week Range0.83 - 11.43
Volume464,404
Avg. Volume822,641
Market Cap22.397M
Beta3.05
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    LIVONIA, Mich., Aug. 13, 2018-- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia ...

  • MarketWatch11 days ago

    Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems'

    Shares of Gemphire Therapeutics Inc. (gemp) plunged 17% toward a record low Friday after the biopharmaceutical company said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems." The company said the data and safety monitoring board at Emory University overseeing the trial recommended the termination. Gemphire said data on the first three patients undergoing 12 weeks of treatment all experienced an increase in liver fat content, which was deemed an unexpected problem.

  • GlobeNewswire11 days ago

    Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver disease (NAFLD) has recommended that the trial be terminated due to unanticipated problems. This pediatric NAFLD trial was initiated in early 2018. Patients were treated with gemcabene at a dose of 300 mg once daily.

  • Benzinga13 days ago

    The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 6) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: ...

  • GlobeNewswire14 days ago

    Gemphire Provides Update On Development of Gemcabene

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has requested that the Company produce data from a sub-chronic toxicology study to provide information to support lifting the partial clinical hold on gemcabene with respect to clinical trials of longer than six months in duration. The FDA also informed the Company that the End of Phase 2 meeting, and consequently the initiation of Phase 3 trials investigating gemcabene in dyslipidemia indications and long-term safety exposure trials needed for registration, will not take place until the partial hold has been lifted.

  • GlobeNewswire14 days ago

    Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has amended and restated the license agreement with Pfizer Inc. covering gemcabene. Gemphire licensed exclusive worldwide commercial rights to gemcabene from Pfizer in an agreement signed in April 2011. Under the original agreement, Pfizer had the right to terminate the license if the drug was not adequately commercialized by April 2021.

  • What’s behind Gemphire Therapeutics’ Stock Price Rise
    Market Realistlast month

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.

  • Why Gemphire Therapeutics Stock Is Rising Today
    Market Realist2 months ago

    Why Gemphire Therapeutics Stock Is Rising Today

    Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint of significantly reducing triglyceride levels in Severe Hypertriglyceridemia (or SHTG) patients with baseline serum triglyceride levels greater than 500 mg/dl. The drug also demonstrated a solid safety and tolerability profile and could be safely combined with other drugs. Gemcabene currently holds a method patent in SHTG indication valid until 2032. ...

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.

  • GlobeNewswire2 months ago

    Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it achieved the primary endpoint, reduction of TGs by gemcabene, in its Phase 2b INDIGO-1 trial in SHTG patients with baseline serum TGs 500 mg/dL.

  • Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important
    Simply Wall St.3 months ago

    Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important

    I am going to take a deep dive into Gemphire Therapeutics Inc’s (NASDAQ:GEMP) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT

    Q4 2017 Gemphire Therapeutics Inc Earnings Call

  • Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?
    Simply Wall St.5 months ago

    Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic?

    Gemphire Therapeutics Inc’s (NASDAQ:GEMP): Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitisRead More...

  • Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
    Zacks6 months ago

    Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?

    Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.